| 001 | 165374 | ||
| 005 | 20240318103532.0 | ||
| 024 | 7 | _ | |a 10.1038/s41591-022-02076-8 |2 doi |
| 024 | 7 | _ | |a pmid:36253611 |2 pmid |
| 024 | 7 | _ | |a 1078-8956 |2 ISSN |
| 024 | 7 | _ | |a 1546-170X |2 ISSN |
| 024 | 7 | _ | |a altmetric:137338203 |2 altmetric |
| 037 | _ | _ | |a DZNE-2022-01648 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Dam, Tien |0 0000-0002-7786-5825 |b 0 |
| 245 | _ | _ | |a Author Correction: Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial. |
| 260 | _ | _ | |a New York, NY |c 2023 |b Nature America Inc. |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1701772393_15102 |2 PUB:(DE-HGF) |x Erratum/Correction |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 536 | _ | _ | |a 353 - Clinical and Health Care Research (POF4-353) |0 G:(DE-HGF)POF4-353 |c POF4-353 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de |
| 700 | 1 | _ | |a Boxer, Adam L |b 1 |
| 700 | 1 | _ | |a Golbe, Lawrence I |b 2 |
| 700 | 1 | _ | |a Höglinger, Günter |0 P:(DE-2719)2811373 |b 3 |u dzne |
| 700 | 1 | _ | |a Morris, Huw R |0 0000-0002-5473-3774 |b 4 |
| 700 | 1 | _ | |a Litvan, Irene |0 0000-0002-3485-3445 |b 5 |
| 700 | 1 | _ | |a Lang, Anthony E |b 6 |
| 700 | 1 | _ | |a Corvol, Jean-Christophe |b 7 |
| 700 | 1 | _ | |a Aiba, Ikuko |b 8 |
| 700 | 1 | _ | |a Grundman, Michael |b 9 |
| 700 | 1 | _ | |a Yang, Lili |b 10 |
| 700 | 1 | _ | |a Tidemann-Miller, Beth |b 11 |
| 700 | 1 | _ | |a Kupferman, Joseph |b 12 |
| 700 | 1 | _ | |a Harper, Kristine |b 13 |
| 700 | 1 | _ | |a Kamisoglu, Kubra |0 0000-0001-6620-0564 |b 14 |
| 700 | 1 | _ | |a Wald, Michael J |b 15 |
| 700 | 1 | _ | |a Graham, Danielle L |b 16 |
| 700 | 1 | _ | |a Gedney, Liz |b 17 |
| 700 | 1 | _ | |a O'Gorman, John |b 18 |
| 700 | 1 | _ | |a Haeberlein, Samantha Budd |b 19 |
| 700 | 1 | _ | |a Group, PASSPORT Study |b 20 |e Collaboration Author |
| 700 | 1 | _ | |a Aiba, Ikuko |b 21 |
| 700 | 1 | _ | |a Antonini, Angelo |b 22 |
| 700 | 1 | _ | |a Apetauerova, Diana |b 23 |
| 700 | 1 | _ | |a Azulay, Jean-Philippe |b 24 |
| 700 | 1 | _ | |a Martinez, Ernest Balaguer |b 25 |
| 700 | 1 | _ | |a Bang, Jee |b 26 |
| 700 | 1 | _ | |a Barone, Paolo |b 27 |
| 700 | 1 | _ | |a Barrett, Matthew |b 28 |
| 700 | 1 | _ | |a Bega, Danny |b 29 |
| 700 | 1 | _ | |a Berg, Daniela |0 P:(DE-2719)2000059 |b 30 |u dzne |
| 700 | 1 | _ | |a Corrales, Koldo Berganzo |b 31 |
| 700 | 1 | _ | |a Bordelon, Yvette |b 32 |
| 700 | 1 | _ | |a Boxer, Adam L |b 33 |
| 700 | 1 | _ | |a Brandt, Moritz |0 P:(DE-2719)2812107 |b 34 |u dzne |
| 700 | 1 | _ | |a Brueggemann, Norbert |b 35 |
| 700 | 1 | _ | |a Castelnovo, Giovanni |b 36 |
| 700 | 1 | _ | |a Ceravolo, Roberto |b 37 |
| 700 | 1 | _ | |a Chuang, Rosalind |b 38 |
| 700 | 1 | _ | |a Chung, Sun Ju |b 39 |
| 700 | 1 | _ | |a Church, Alistair |b 40 |
| 700 | 1 | _ | |a Corvol, Jean-Christophe |b 41 |
| 700 | 1 | _ | |a Cudia, Paola |b 42 |
| 700 | 1 | _ | |a Dale, Marian |b 43 |
| 700 | 1 | _ | |a Defebvre, Luc |b 44 |
| 700 | 1 | _ | |a Drapier, Sophie |b 45 |
| 700 | 1 | _ | |a Driver-Dunckley, Erika D |b 46 |
| 700 | 1 | _ | |a Ebersbach, Georg |b 47 |
| 700 | 1 | _ | |a Eggert, Karla M |b 48 |
| 700 | 1 | _ | |a Ellenbogen, Aaron |b 49 |
| 700 | 1 | _ | |a Eusebio, Alexandre |b 50 |
| 700 | 1 | _ | |a Evans, Andrew H |b 51 |
| 700 | 1 | _ | |a Fedorova, Natalia |b 52 |
| 700 | 1 | _ | |a Finger, Elizabeth |b 53 |
| 700 | 1 | _ | |a Foubert-Samier, Alexandra |b 54 |
| 700 | 1 | _ | |a Ghosh, Boyd |b 55 |
| 700 | 1 | _ | |a Golbe, Lawrence |b 56 |
| 700 | 1 | _ | |a Perez, Francisco Grandas |b 57 |
| 700 | 1 | _ | |a Grossman, Murray |b 58 |
| 700 | 1 | _ | |a Hall, Deborah |b 59 |
| 700 | 1 | _ | |a Hamada, Kyoko |b 60 |
| 700 | 1 | _ | |a Hasegawa, Kazuko |b 61 |
| 700 | 1 | _ | |a Hoeglinger, Guenter |b 62 |
| 700 | 1 | _ | |a Honig, Lawrence |b 63 |
| 700 | 1 | _ | |a Houghton, David |b 64 |
| 700 | 1 | _ | |a Huang, Xuemei |b 65 |
| 700 | 1 | _ | |a Isaacson, Stuart |b 66 |
| 700 | 1 | _ | |a Koh, SeongBeom |b 67 |
| 700 | 1 | _ | |a Bojarski, Jaime Kulisevsky |b 68 |
| 700 | 1 | _ | |a Lang, Anthony E |b 69 |
| 700 | 1 | _ | |a Leigh, Peter Nigel |b 70 |
| 700 | 1 | _ | |a Litvan, Irene |b 71 |
| 700 | 1 | _ | |a Lozano, Juan Jose Lopez |b 72 |
| 700 | 1 | _ | |a Moreno, Jose Luis Lopez-Sendon |b 73 |
| 700 | 1 | _ | |a Ludolph, Albert Christian |0 P:(DE-2719)2812633 |b 74 |u dzne |
| 700 | 1 | _ | |a Piudo, Ma Rosario Luquin |b 75 |
| 700 | 1 | _ | |a Torres, Irene Martinez |b 76 |
| 700 | 1 | _ | |a McFarland, Nikolaus |b 77 |
| 700 | 1 | _ | |a Meissner, Wassilios |b 78 |
| 700 | 1 | _ | |a Mestre, Tiago |b 79 |
| 700 | 1 | _ | |a Rivera, Pablo Mir |b 80 |
| 700 | 1 | _ | |a Molho, Eric |b 81 |
| 700 | 1 | _ | |a Mollenhauer, Britt |b 82 |
| 700 | 1 | _ | |a Morris, Huw R |b 83 |
| 700 | 1 | _ | |a Murata, Miho |b 84 |
| 700 | 1 | _ | |a Obi, Tomokazu |b 85 |
| 700 | 1 | _ | |a Magne, Fabienne Ory |b 86 |
| 700 | 1 | _ | |a O'Suilleabhain, Padraig |b 87 |
| 700 | 1 | _ | |a Pahwa, Rajesh |b 88 |
| 700 | 1 | _ | |a Pantelyat, Alexander |b 89 |
| 700 | 1 | _ | |a Pavese, Nicola |b 90 |
| 700 | 1 | _ | |a Pokhabov, Dmitry |b 91 |
| 700 | 1 | _ | |a Prudlo, Johannes |0 P:(DE-2719)2380559 |b 92 |u dzne |
| 700 | 1 | _ | |a Rodriguez-Porcel, Federico |b 93 |
| 700 | 1 | _ | |a Rowe, James |b 94 |
| 700 | 1 | _ | |a Savitt, Joseph |b 95 |
| 700 | 1 | _ | |a Schnitzler, Alfons |b 96 |
| 700 | 1 | _ | |a Schulz, Joerg B |b 97 |
| 700 | 1 | _ | |a Seppi, Klaus |b 98 |
| 700 | 1 | _ | |a Shah, Binit |b 99 |
| 700 | 1 | _ | |a Shill, Holly |b 100 |
| 700 | 1 | _ | |a Shprecher, David |b 101 |
| 700 | 1 | _ | |a Stamelou, Maria |b 102 |
| 700 | 1 | _ | |a Steiger, Malcolm |b 103 |
| 700 | 1 | _ | |a Takahashi, Yuji |b 104 |
| 700 | 1 | _ | |a Takigawa, Hiroshi |b 105 |
| 700 | 1 | _ | |a Tartaglia, Carmela |b 106 |
| 700 | 1 | _ | |a Toenges, Lars |b 107 |
| 700 | 1 | _ | |a Truong, Daniel |b 108 |
| 700 | 1 | _ | |a Tse, Winona |b 109 |
| 700 | 1 | _ | |a Tuite, Paul |b 110 |
| 700 | 1 | _ | |a Volc, Dieter |b 111 |
| 700 | 1 | _ | |a Wills, Anne-Marie A |b 112 |
| 700 | 1 | _ | |a Woitalla, Dirk |b 113 |
| 700 | 1 | _ | |a Xie, Tao |b 114 |
| 700 | 1 | _ | |a Yuasa, Tatsuhiko |b 115 |
| 700 | 1 | _ | |a Zauber, Sarah Elizabeth |b 116 |
| 700 | 1 | _ | |a Zesiewicz, Theresa |b 117 |
| 773 | _ | _ | |a 10.1038/s41591-022-02076-8 |0 PERI:(DE-600)1484517-9 |n 11 |p 2955 - 2956 |t Nature medicine |v 29 |y 2023 |x 1078-8956 |
| 787 | 0 | _ | |a Dam, Tien et.al. |d New York, NY : Nature America Inc., 2021 |i RelatedTo |0 DZNE-2021-01399 |r |t Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial. |
| 856 | 4 | _ | |u https://www.nature.com/articles/s41591-022-02076-8 |
| 856 | 4 | _ | |u https://pub.dzne.de/record/165374/files/DZNE-2022-01648_Restricted.pdf |
| 856 | 4 | _ | |u https://pub.dzne.de/record/165374/files/DZNE-2022-01648_Restricted.pdf?subformat=pdfa |x pdfa |
| 909 | C | O | |p VDB |o oai:pub.dzne.de:165374 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 3 |6 P:(DE-2719)2811373 |
| 910 | 1 | _ | |a External Institute |0 I:(DE-HGF)0 |k Extern |b 30 |6 P:(DE-2719)2000059 |
| 910 | 1 | _ | |a External Institute |0 I:(DE-HGF)0 |k Extern |b 34 |6 P:(DE-2719)2812107 |
| 910 | 1 | _ | |a External Institute |0 I:(DE-HGF)0 |k Extern |b 74 |6 P:(DE-2719)2812633 |
| 910 | 1 | _ | |a External Institute |0 I:(DE-HGF)0 |k Extern |b 92 |6 P:(DE-2719)2380559 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Neurodegenerative Diseases |1 G:(DE-HGF)POF4-350 |0 G:(DE-HGF)POF4-353 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Clinical and Health Care Research |x 0 |
| 914 | 1 | _ | |y 2023 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2021-02-03 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1190 |2 StatID |b Biological Abstracts |d 2021-02-03 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2021-02-03 |
| 915 | _ | _ | |a Nationallizenz |0 StatID:(DE-HGF)0420 |2 StatID |d 2023-08-29 |w ger |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2023-08-29 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2023-08-29 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2023-08-29 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2023-08-29 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |d 2023-08-29 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |d 2023-08-29 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b NAT MED : 2022 |d 2023-08-29 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2023-08-29 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |d 2023-08-29 |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |d 2023-08-29 |
| 915 | _ | _ | |a IF >= 80 |0 StatID:(DE-HGF)9980 |2 StatID |b NAT MED : 2022 |d 2023-08-29 |
| 920 | 1 | _ | |0 I:(DE-2719)1111015 |k Clinical Research (Munich) |l Clinical Research (Munich) |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-2719)1111015 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|
guest ::